Jimmunol.1202493.Full.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Jimmunol.1202493.Full.Pdf Published February 13, 2013, doi:10.4049/jimmunol.1202493 The Journal of Immunology Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis Christoph J. Heuck,* Jayesh Mehta,† Tushar Bhagat,* Krishna Gundabolu,* Yiting Yu,* Shahper Khan,‡ Grigoris Chrysofakis,* Carolina Schinke,* Joseph Tariman,† Eric Vickrey,† Natalie Pulliam,† Sangeeta Nischal,* Li Zhou,* Sanchari Bhattacharya,* Richard Meagher,† Caroline Hu,* Shahina Maqbool,* Masako Suzuki,* Samir Parekh,* Frederic Reu,‡ Ulrich Steidl,* John Greally,* Amit Verma,* and Seema B. Singhal† Epigenetic changes play important roles in carcinogenesis and influence initial steps in neoplastic transformation by altering ge- nome stability and regulating gene expression. To characterize epigenomic changes during the transformation of normal plasma cells to myeloma, we modified the HpaII tiny fragment enrichment by ligation–mediated PCR assay to work with small numbers of purified primary marrow plasma cells. The nano-HpaII tiny fragment enrichment by ligation–mediated PCR assay was used to analyze the methylome of CD138+ cells from 56 subjects representing premalignant (monoclonal gammopathy of uncertain significance), early, and advanced stages of myeloma, as well as healthy controls. Plasma cells from premalignant and early stages of myeloma were characterized by striking, widespread hypomethylation. Gene-specific hypermethylation was seen to occur in the advanced stages, and cell lines representative of relapsed cases were found to be sensitive to decitabine. Aberrant demethylation in monoclonal gammopathy of uncertain significance occurred primarily in CpG islands, whereas differentially methylated loci in cases of myeloma occurred predominantly outside of CpG islands and affected distinct sets of gene pathways, demonstrating qualitative epigenetic differences between premalignant and malignant stages. Examination of the methylation machinery revealed that the methyltransferase, DNMT3A, was aberrantly hypermethylated and underexpressed, but not mutated in mye- loma. DNMT3A underexpression was also associated with adverse overall survival in a large cohort of patients, providing insights into genesis of hypomethylation in myeloma. These results demonstrate widespread, stage-specific epigenetic changes during myelomagenesis and suggest that early demethylation can be a potential contributor to genome instability seen in myeloma. We also identify DNMT3A expression as a novel prognostic biomarker and suggest that relapsed cases can be therapeutically targeted by hypomethylating agents. The Journal of Immunology, 2013, 190: 000–000. espite therapeutic advances, multiple myeloma (MM) re- the development of a risk model that remains robust even in the age mains incurable and needs newer insights into the path- of newer therapies (1). The use of gene expression profiling by D ogenic mechanisms that cause this disease. Gene expres- different groups has also led to the identification of distinct mo- sion profiling has been used extensively in myeloma and has led to lecular subgroups that show defined clinical features (2, 3). How- ever, pathogenic mechanisms driving these differences in gene expression have not been well described, especially for early stages *Albert Einstein College of Medicine, Bronx, NY 10461; †Northwestern University, in myelomagenesis (4). Feinberg School of Medicine, Chicago, IL 60611; and ‡Cleveland Clinic, Cleveland, Recent studies of the epigenome and in particular the methylome OH 44195 have shown that cancer is characterized by widespread epigenetic Received for publication September 7, 2012. Accepted for publication January 9, changes. These changes lead to altered gene expression that can 2013. result in activation of oncogenic pathways. Furthermore, methyl- This work was supported by National Institutes of Health Immunooncology Training ome profiling has shown greater prognostic ability than gene ex- Program Grant T32 CA009173, Gabrielle’s Angel Foundation, the Leukemia and Lymphoma Society, the American Cancer Society, the Department of Defense, and pression profiling in acute myeloid leukemia (AML) and has led to a Partnership for Cures grant. identification of newer molecular subgroups with differences in The methylation data presented in this article have been deposited in the National overall survival (5). We have shown that methylome profiling is Institutes of Health Gene Expression Omnibus (National Center for Biotechnology able to identify changes that occur early during carcinogenesis in Information, http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE 43860. solid tumors such as esophageal cancer (6). These studies have Address correspondence and reprint requests to Dr. Amit Verma, Dr. Christoph J. Heuck, and Dr. Seema B. Singhal, Albert Einstein College of Medicine, Bronx, NY been conducted with the use of the HpaII tiny fragment enrich- 10461 (A.V. and C.J.H.) and Feinberg School of Medicine, Northwestern University, ment by ligation–mediated PCR (HELP) assay, which is a ge- Chicago, IL 60611 (S.B.S.). E-mail addresses: [email protected] (A.V.), nome-wide assay that provides a reproducible analysis of the [email protected] (C.J.H.), and [email protected] (S.B.S.) methylome that is not biased toward CpG islands (7). Analyzing The online version of this article contains supplemental material. the methylome of myeloma can help identify changes that can Abbreviations used in this article: AML, acute myeloid leukemia; HAF, HpaII-amplifi- able fragment; HELP, HpaII tiny fragment enrichment by ligation–mediated PCR; MM, define disease subsets and lead to identification of newer thera- multiple myeloma; MGUS, monoclonal gammopathy of uncertain significance; peutic targets. Recent sequencing studies in myeloma have also NEWMM, newly diagnosed myeloma; NL, normal; REL, relapsed myeloma; REM, revealed mutations in enzymes that are involved in epigenetic complete remission; SMM, smoldering myeloma; TF, transcription factor. machinery, again reinforcing the need to study the epigenetic Copyright Ó 2013 by The American Association of Immunologists, Inc. 0022-1767/13/$16.00 alterations in this disease (8). We have conducted a genome-wide www.jimmunol.org/cgi/doi/10.4049/jimmunol.1202493 2 METHYLOME OF MULTIPLE MYELOMA analysis of changes in DNA methylation in monoclonal gamm- tative for methylation and analyzed as a continuous variable. For most loci, opathy of uncertain significance (MGUS), newly diagnosed MM, each fragment was categorized as either methylated, if the centered log , as well as relapsed MM, and compared them with normal plasma HpaII/MspI ratio was generally 0, or hypomethylated, if, in contrast, the log ratio was .0. cell controls. We used a modification of the HELP assay (nano- HELP) that was developed to work with low amounts of DNA to Quantitative DNA methylation analysis by MassArray interrogate the methylome of sorted CD138+ cells from patient Epityping samples. We report that widespread alterations in DNA methyla- Validation of the findings of the HELP assay was carried out by MALDI- tion are seen in myeloma and have the power to discriminate TOF mass spectrometry using EpiTyper by MassArray (Sequenom, CA) on between MGUS and new/relapsed cases. We report that hypo- bisulfite-converted DNA, as previously described (6). Validation was done methylation is the predominant early change during myeloma- on all samples with sufficient available DNA. MassARRAY primers were designed to cover the flanking HpaII sites for a given HAF, as well as for genesis that is gradually transformed to hypermethylation in any other HpaII sites found up to 2000 bp upstream of the downstream site relapsed cases, thus providing the epigenetic basis for the differ- and up to 2000 bp downstream of the upstream site, to cover all possible entiation between these different stages of myeloma. alternative sites of digestion within our range of PCR amplification. Microarray data analysis Materials and Methods Patient samples Unsupervised clustering of HELP data by hierarchical clustering was performed using the statistical software R version 2.6.2. A two-sample t test Bone marrow aspirates were obtained with signed informed consent from was used for each gene to summarize methylation differences between 11 patients with MGUS, 4 patients with smoldering myeloma (SMM), groups. Genes were ranked on the basis of this test statistic, and a set of top 13 patients with newly diagnosed myeloma (NEWMM), 16 patients with differentially methylated genes with an observed log fold change of .1 relapsed myeloma (REL), including 2 patients with serial samples, and 2 between group means was identified. Genes were further grouped patients in clinical complete remission (REM) who are followed at the according to the direction of the methylation change (hypomethylated myeloma clinic at the Robert H. Lurie Cancer Center at Northwestern versus hypermethylated), and the relative frequencies of these changes University. All specimens underwent CD138+ microbead selection (Mil- were computed among the top candidates to explore global methylation tenyi Biotec). Purity was confirmed by flow cytometry staining for CD38 patterns. Validation with MassArray showed good correlation with the data and CD45. Samples with a purity ,90% by flow cytometry were not used generated by the HELP assay. MassArray analysis validated significant for this study. Eight samples from normal donors without known malig- quantitative differences in methylation for differentially
Recommended publications
  • CDX4 Regulates the Progression of Neural Maturation in the Spinal Cord
    Developmental Biology 449 (2019) 132–142 Contents lists available at ScienceDirect Developmental Biology journal homepage: www.elsevier.com/locate/developmentalbiology CDX4 regulates the progression of neural maturation in the spinal cord Piyush Joshi a,b, Andrew J. Darr c, Isaac Skromne a,d,* a Department of Biology, University of Miami, 1301 Memorial Drive, Coral Gables, Florida, 33146, United States b Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, 600 5th St S, St. Petersburg, FL 33701, United States c Department of Health Sciences Education, University of Illinois College of Medicine, 1 Illini Drive, Peoria, IL 61605, United States d Department of Biology, University of Richmond, 138 UR Drive B322, Richmond, VA, 23173, United States ARTICLE INFO ABSTRACT Keywords: The progression of cells down different lineage pathways is a collaborative effort between networks of extra- CDX cellular signals and intracellular transcription factors. In the vertebrate spinal cord, FGF, Wnt and Retinoic Acid Neurogenesis signaling pathways regulate the progressive caudal-to-rostral maturation of neural progenitors by regulating a Spinal cord poorly understood gene regulatory network of transcription factors. We have mapped out this gene regulatory Gene regulatory network network in the chicken pre-neural tube, identifying CDX4 as a dual-function core component that simultaneously regulates gradual loss of cell potency and acquisition of differentiation states: in a caudal-to-rostral direction, CDX4 represses the early neural differentiation marker Nkx1.2 and promotes the late neural differentiation marker Pax6. Significantly, CDX4 prevents premature PAX6-dependent neural differentiation by blocking Ngn2 activation. This regulation of CDX4 over Pax6 is restricted to the rostral pre-neural tube by Retinoic Acid signaling.
    [Show full text]
  • Genetic Associations Between Voltage-Gated Calcium Channels (Vgccs) and Autism Spectrum Disorder (ASD)
    Liao and Li Molecular Brain (2020) 13:96 https://doi.org/10.1186/s13041-020-00634-0 REVIEW Open Access Genetic associations between voltage- gated calcium channels and autism spectrum disorder: a systematic review Xiaoli Liao1,2 and Yamin Li2* Abstract Objectives: The present review systematically summarized existing publications regarding the genetic associations between voltage-gated calcium channels (VGCCs) and autism spectrum disorder (ASD). Methods: A comprehensive literature search was conducted to gather pertinent studies in three online databases. Two authors independently screened the included records based on the selection criteria. Discrepancies in each step were settled through discussions. Results: From 1163 resulting searched articles, 28 were identified for inclusion. The most prominent among the VGCCs variants found in ASD were those falling within loci encoding the α subunits, CACNA1A, CACNA1B, CACN A1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, and CACNA1I as well as those of their accessory subunits CACNB2, CACNA2D3, and CACNA2D4. Two signaling pathways, the IP3-Ca2+ pathway and the MAPK pathway, were identified as scaffolds that united genetic lesions into a consensus etiology of ASD. Conclusions: Evidence generated from this review supports the role of VGCC genetic variants in the pathogenesis of ASD, making it a promising therapeutic target. Future research should focus on the specific mechanism that connects VGCC genetic variants to the complex ASD phenotype. Keywords: Autism spectrum disorder, Voltage-gated calcium
    [Show full text]
  • The Mineralocorticoid Receptor Leads to Increased Expression of EGFR
    www.nature.com/scientificreports OPEN The mineralocorticoid receptor leads to increased expression of EGFR and T‑type calcium channels that support HL‑1 cell hypertrophy Katharina Stroedecke1,2, Sandra Meinel1,2, Fritz Markwardt1, Udo Kloeckner1, Nicole Straetz1, Katja Quarch1, Barbara Schreier1, Michael Kopf1, Michael Gekle1 & Claudia Grossmann1* The EGF receptor (EGFR) has been extensively studied in tumor biology and recently a role in cardiovascular pathophysiology was suggested. The mineralocorticoid receptor (MR) is an important efector of the renin–angiotensin–aldosterone‑system and elicits pathophysiological efects in the cardiovascular system; however, the underlying molecular mechanisms are unclear. Our aim was to investigate the importance of EGFR for MR‑mediated cardiovascular pathophysiology because MR is known to induce EGFR expression. We identifed a SNP within the EGFR promoter that modulates MR‑induced EGFR expression. In RNA‑sequencing and qPCR experiments in heart tissue of EGFR KO and WT mice, changes in EGFR abundance led to diferential expression of cardiac ion channels, especially of the T‑type calcium channel CACNA1H. Accordingly, CACNA1H expression was increased in WT mice after in vivo MR activation by aldosterone but not in respective EGFR KO mice. Aldosterone‑ and EGF‑responsiveness of CACNA1H expression was confrmed in HL‑1 cells by Western blot and by measuring peak current density of T‑type calcium channels. Aldosterone‑induced CACNA1H protein expression could be abrogated by the EGFR inhibitor AG1478. Furthermore, inhibition of T‑type calcium channels with mibefradil or ML218 reduced diameter, volume and BNP levels in HL‑1 cells. In conclusion the MR regulates EGFR and CACNA1H expression, which has an efect on HL‑1 cell diameter, and the extent of this regulation seems to depend on the SNP‑216 (G/T) genotype.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • ZNF652, a Novel Zinc Finger Protein, Interacts with the Putative Breast Tumor Suppressor CBFA2T3 to Repress Transcription
    ZNF652, A Novel Zinc Finger Protein, Interacts with the Putative Breast Tumor Suppressor CBFA2T3 to Repress Transcription Raman Kumar,1 Jantina Manning,1 Hayley E. Spendlove,3 Gabriel Kremmidiotis,4 Ross McKirdy,1 Jaclyn Lee,1 David N. Millband,1 Kelly M. Cheney,1 Martha R. Stampfer,5 Prem P. Dwivedi,2 Howard A. Morris,2 and David F. Callen1 1Breast Cancer Genetics Group, Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide and Hanson Institute; 2Endocrine Bone Laboratory, Hanson Institute, Adelaide, South Australia, Australia; 3Department of Laboratory Genetics, Women’s and Children’s Hospital, North Adelaide, South Australia, Australia; 4Bionomics, Ltd., Thebarton, South Australia, Australia; and 5Lawrence Berkeley National Laboratory, Berkeley, California Abstract gene effector zinc finger proteins may specifically The transcriptional repressor CBFA2T3is a putative interact with one or more of the ETO proteins to generate breast tumor suppressor. To define the role of CBFA2T3, a defined range of transcriptional repressor complexes. we used a segment of this protein as bait in a yeast (Mol Cancer Res 2006;4(9):655–65) two-hybrid screen and identified a novel uncharacterized protein, ZNF652. In general, primary tumors and cancer Introduction cell lines showed lower expression of ZNF652 than Tumor growth, characterized by unchecked cell division, normal tissues. Together with the location of this gene results from both the overexpression of growth-promoting on the long arm of chromosome 17q, a region of frequent oncogenes and the reduced expression of growth-inhibiting loss of heterozygosity in cancer, these results suggest tumor suppressor genes. These genes often encode proteins that In silico a possible role of ZNF652 in tumorigenesis.
    [Show full text]
  • CCAAT/Enhancer Binding Protein Epsilon) Thomas Burmeister Charite, Med
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Gene Section Short Communication CEBPE (CCAAT/enhancer binding protein epsilon) Thomas Burmeister Charite, Med. Klinik fur Hamatologie, Onkologie und Tumorimmunologie, Hindenburgdamm 30, 12200 Berlin, Germany; [email protected] Published in Atlas Database: March 2017 Online updated version : http://AtlasGeneticsOncology.org/Genes/CEBPEID42984ch14q11.html Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/69005/03-2017-CEBPEID42984ch14q11.pdf DOI: 10.4267/2042/69005 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology alternative 3-exon-organization of the human Abstract CEBPE gene (Figure 1b). However, exon 1, as described by Yamanaka et al. contains a frameshift Review on CEBPE, with data on DNA, on the according to the GRCh38.p7 NCBI assembly. protein encoded, and where the gene is implicated. Transcription Keywords CEBPE; Transcription factor; Neutrophil specific Various transcripts have been reported, resulting in granule deficiency; Acute lymphoblastic leukemia; four protein isoforms (Lekstrom-Himes 2001, Translocation. Yamanaka 1997; Figure 1c). All transcripts share a common 3' end. Identity Protein Other names: CRP1 Description HGNC (Hugo): CEBPE CEBPE is a member of the CCAAT/enhancer- Location: 14q11.2 binding protein (C/EBP) family, which also Location (base pair) includes CEBPA, CEBPB, CEBPG, CEBPD and Starts at 23117306 and ends at 23119611 bp from CEBPZ (Ramji & Foka; 2002). A common pter (according to GRCh38.p7 Annotation Release structural feature of the C/EBP proteins is the 108, May 5 2016) presence of a highly conserved 55-65 amino acid sequence at the C-terminus which encodes a basic DNA/RNA leucine zipper motif (bZIP domain) that functions as a dimerization domain.
    [Show full text]
  • Jmjd2c Facilitates the Assembly of Essential Enhancer-Protein Complexes at the Onset of Embryonic Stem Cell Differentiation Rute A
    © 2017. Published by The Company of Biologists Ltd | Development (2017) 144, 567-579 doi:10.1242/dev.142489 STEM CELLS AND REGENERATION RESEARCH ARTICLE Jmjd2c facilitates the assembly of essential enhancer-protein complexes at the onset of embryonic stem cell differentiation Rute A. Tomaz1,JenniferL.Harman2, Donja Karimlou1, Lauren Weavers1, Lauriane Fritsch3, Tony Bou-Kheir1, Emma Bell1, Ignacio del Valle Torres4, Kathy K. Niakan4,CynthiaFisher5, Onkar Joshi6, Hendrik G. Stunnenberg6, Edward Curry1, Slimane Ait-Si-Ali3, Helle F. Jørgensen2 and Véronique Azuara1,* ABSTRACT implantation, a second extra-embryonic lineage, the primitive Jmjd2 H3K9 demethylases cooperate in promoting mouse embryonic endoderm, emerges at the ICM surface. Concurrently, the ICM stem cell (ESC) identity. However, little is known about their maintains its pluripotency as it matures into the epiblast but importance at the exit of ESC pluripotency. Here, we reveal that ultimately goes on to form the three primary germ layers and germ Jmjd2c facilitates this process by stabilising the assembly of cells upon gastrulation (Boroviak and Nichols, 2014; Rossant, mediator-cohesin complexes at lineage-specific enhancers. 2008). Functionally, we show that Jmjd2c is required in ESCs to initiate Pluripotent mouse embryonic stem cells (ESCs) are derived from appropriate gene expression programs upon somatic multi-lineage ICM cells, and can self-renew and faithfully maintain an differentiation. In the absence of Jmjd2c, differentiation is stalled at an undifferentiated state in vitro in the presence of leukaemia inhibitory early post-implantation epiblast-like stage, while Jmjd2c-knockout factor (LIF) and serum components, while preserving their multi- ESCs remain capable of forming extra-embryonic endoderm lineage differentiation capacity (Evans and Kaufman, 1981; Martin, derivatives.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Seq2pathway Vignette
    seq2pathway Vignette Bin Wang, Xinan Holly Yang, Arjun Kinstlick May 19, 2021 Contents 1 Abstract 1 2 Package Installation 2 3 runseq2pathway 2 4 Two main functions 3 4.1 seq2gene . .3 4.1.1 seq2gene flowchart . .3 4.1.2 runseq2gene inputs/parameters . .5 4.1.3 runseq2gene outputs . .8 4.2 gene2pathway . 10 4.2.1 gene2pathway flowchart . 11 4.2.2 gene2pathway test inputs/parameters . 11 4.2.3 gene2pathway test outputs . 12 5 Examples 13 5.1 ChIP-seq data analysis . 13 5.1.1 Map ChIP-seq enriched peaks to genes using runseq2gene .................... 13 5.1.2 Discover enriched GO terms using gene2pathway_test with gene scores . 15 5.1.3 Discover enriched GO terms using Fisher's Exact test without gene scores . 17 5.1.4 Add description for genes . 20 5.2 RNA-seq data analysis . 20 6 R environment session 23 1 Abstract Seq2pathway is a novel computational tool to analyze functional gene-sets (including signaling pathways) using variable next-generation sequencing data[1]. Integral to this tool are the \seq2gene" and \gene2pathway" components in series that infer a quantitative pathway-level profile for each sample. The seq2gene function assigns phenotype-associated significance of genomic regions to gene-level scores, where the significance could be p-values of SNPs or point mutations, protein-binding affinity, or transcriptional expression level. The seq2gene function has the feasibility to assign non-exon regions to a range of neighboring genes besides the nearest one, thus facilitating the study of functional non-coding elements[2]. Then the gene2pathway summarizes gene-level measurements to pathway-level scores, comparing the quantity of significance for gene members within a pathway with those outside a pathway.
    [Show full text]
  • Transcriptomic Analysis of the Aquaporin (AQP) Gene Family
    Pancreatology 19 (2019) 436e442 Contents lists available at ScienceDirect Pancreatology journal homepage: www.elsevier.com/locate/pan Transcriptomic analysis of the Aquaporin (AQP) gene family interactome identifies a molecular panel of four prognostic markers in patients with pancreatic ductal adenocarcinoma Dimitrios E. Magouliotis a, b, Vasiliki S. Tasiopoulou c, Konstantinos Dimas d, * Nikos Sakellaridis d, Konstantina A. Svokos e, Alexis A. Svokos f, Dimitris Zacharoulis b, a Division of Surgery and Interventional Science, Faculty of Medical Sciences, UCL, London, UK b Department of Surgery, University of Thessaly, Biopolis, Larissa, Greece c Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Larissa, Greece d Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Larissa, Greece e The Warren Alpert Medical School of Brown University, Providence, RI, USA f Riverside Regional Medical Center, Newport News, VA, USA article info abstract Article history: Background: This study aimed to assess the differential gene expression of aquaporin (AQP) gene family Received 14 October 2018 interactome in pancreatic ductal adenocarcinoma (PDAC) using data mining techniques to identify novel Received in revised form candidate genes intervening in the pathogenicity of PDAC. 29 January 2019 Method: Transcriptome data mining techniques were used in order to construct the interactome of the Accepted 9 February 2019 AQP gene family and to determine which genes members are differentially expressed in PDAC as Available online 11 February 2019 compared to controls. The same techniques were used in order to evaluate the potential prognostic role of the differentially expressed genes. Keywords: PDAC Results: Transcriptome microarray data of four GEO datasets were incorporated, including 142 primary Aquaporin tumor samples and 104 normal pancreatic tissue samples.
    [Show full text]
  • Regulation of Transcription and Regulatory Networks for Muscle Growth * * * * A
    Regulation Of Transcription And Regulatory Networks For Muscle Growth * * * * A. Reverter , N.J. Hudson , Q. Gu and B.P. Dalrymple Introduction The advent of microarray gene expression technology has provided animal scientists with an unprecedented ability to profile the transcriptional changes during skeletal muscle growth. With respect to meat quality, most of the effort has concentrated on the understanding of fat and energy metabolism (reviewed by Hausman et al . (2009)). Graugnard et al . (2009) explored the network among 31 genes associated with aspects of adipogenesis and energy metabolism in bovine skeletal muscle and in response to two distinct diets. Also, Freyssenet (2007) reviewed the roles that energy-sensing molecules and mitochondria have in the regulation of gene expression in muscle. However, other mechanisms such as cell cycle, glycolysis, extra-cellular matrix, ribosomal proteins and the immune system play a significant role in development, and this role can work in a tissue-specific manner. Hudson et al . (2009a) reported various functional modules underpinning the transcriptional regulation of bovine skeletal muscle. The authors integrated a total of six gene co-expression networks, each developed using the PCIT algorithm (Reverter and Chan (2008)), and proposed a Module-to-Regulator heuristic by which those transcription factors (TF) with the highest average absolute correlation co-expression with the genes present in each module are deemed to be the relevant regulators. However, this Module-to-Regulator approach failed to capture some well-known regulators of muscle fibre type composition, and the use of more sophisticated methods such as the differential wiring approach of Hudson et al .
    [Show full text]
  • Genetic Variability in the Italian Heavy Draught Horse from Pedigree Data and Genomic Information
    Supplementary material for manuscript: Genetic variability in the Italian Heavy Draught Horse from pedigree data and genomic information. Enrico Mancin†, Michela Ablondi†, Roberto Mantovani*, Giuseppe Pigozzi, Alberto Sabbioni and Cristina Sartori ** Correspondence: [email protected] † These two Authors equally contributed to the work Supplementary Figure S1. Mares and foal of Italian Heavy Draught Horse (IHDH; courtesy of Cinzia Stoppa) Supplementary Figure S2. Number of Equivalent Generations (EqGen; above) and pedigree completeness (PC; below) over years in Italian Heavy Draught Horse population. Supplementary Table S1. Descriptive statistics of homozygosity (observed: Ho_obs; expected: Ho_exp; total: Ho_tot) in 267 genotyped individuals of Italian Heavy Draught Horse based on the number of homozygous genotypes. Parameter Mean SD Min Max Ho_obs 35,630.3 500.7 34,291 38,013 Ho_exp 35,707.8 64.0 35,010 35,740 Ho_tot 50,674.5 93.8 49,638 50,714 1 Definitions of the methods for inbreeding are in the text. Supplementary Figure S3. Values of BIC obtained by analyzing values of K from 1 to 10, corresponding on the same amount of clusters defining the proportion of ancestry in the 267 genotyped individuals. Supplementary Table S2. Estimation of genomic effective population size (Ne) traced back to 18 generations ago (Gen. ago). The linkage disequilibrium estimation, adjusted for sampling bias was also included (LD_r2), as well as the relative standard deviation (SD(LD_r2)). Gen. ago Ne LD_r2 SD(LD_r2) 1 100 0.009 0.014 2 108 0.011 0.018 3 118 0.015 0.024 4 126 0.017 0.028 5 134 0.019 0.031 6 143 0.021 0.034 7 156 0.023 0.038 9 173 0.026 0.041 11 189 0.029 0.046 14 213 0.032 0.052 18 241 0.036 0.058 Supplementary Table S3.
    [Show full text]